You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The US Securities and Exchange Commission alleges that uBiome's founders misled investors in order to close a Series C financing round in 2018.
The financing round brings the total amount of funding for Micronoma, a developer of microbiome-based cancer detection technology, to $6.5 million.
The test, called LifeKit Prevent, analyzes microbial genomic biomarkers in stool samples that are strongly associated with specific stages of CRC progression.
The University of California, San Diego spinout is developing a technology that uses microbial DNA signatures for the early detection of cancer.
Natera discussed its cancer and transplant rejection testing businesses, while Exact Sciences explained how it will benefit from its Genomic Health acquisition.
The funding supports development of a low-cost platform for detection of antimicrobial resistance elements in complex microbial communities.
MinIon sequencing identified pathogens and antimicrobial resistance genes in the gut of preterm infants with suspected necrotizing enterocolitis.
The company had previously declared Chapter 11 bankruptcy, which would have enabled it to reorganize to stay afloat and pay its creditors over time.
By examining metagenomic data of bacterial species in a patient's gut, the researchers aim to improve diagnosis and long-term nutritional intervention and treatment.
The researchers said a microbiome-based test could expand the number of individuals who are screened for the disease.